Next-Gen IBD management: smart combination with adjunctive non-pharmacological therapies

Online training in IBD

Integrating complementary non-pharmacological therapies in the management of complex patients

Optimizing outcomes in IBD requires going beyond standard treatment

Despite therapeutic advances, a significant proportion of patients with inflammatory bowel disease (IBD) continue to show a suboptimal response, loss of response or intolerance to the available pharmacological therapies.

This online scientific meeting addresses how the rational integration of complementary non-pharmacological therapies, with unique and differential mechanisms of action, alongside standard treatment of Inflammatory Bowel Disease (IBD), can help improve disease control and optimize clinical outcomes, especially in complex clinical scenarios.

Who is it for?

A training programme for specialists who want to go one step further in the management of IBD.

• Gastroenterologists specialising in IBD
• Specialists managing refractory or difficult-to-control patients
• Clinicians interested in the rationale for use, the mechanisms of action of the therapies used, translational medicine and real-world clinical evidence

Scientific highlights

🔬 Granulocyte and monocyte apheresis (GMA) in IBD: clinical outcomes and real-world experience

• Results of the 6-month interim analysis of the GRACE Study with Adacolumn®
• Patient selection criteria
• Treatment schedules and strategies for use
• Clinical outcomes in routine practice

📌 Presented by one of the study coordinators: Dr. Iago Rodríguez-Lago

🧬 GMA mechanism of action in depth: single-cell evidence

• Preliminary results of the SIMA study (single-cell transcriptomics)
• Immunological impact of GMA as monotherapy and in combination, from a mechanistic perspective
• Modulation of innate immunity

📌 Detailed mechanistic analysis by Dr. Iago Rodríguez-Lago

Rethinking current therapeutic limits in IBD

• Main limitations of the current pharmacological paradigm
• Central role of innate immunity in the pathophysiology of IBD
• Integrating therapies targeting innate immunity into current clinical practice to improve outcomes in IBD

📌 Strategic and scientific vision by Prof. Saurabh Mehandru

🧪 CurQD® in IBD: from biology to the clinic

• Differential mechanism of action of CurQD®
• Clinical relevance of its mechanism of action in IBD
• Clinical experience in IBD: real-world outcomes, with particular focus on the latest published results in Crohn’s disease (CD)

📌 Presented by:
Prof. Shomron Ben-Horin (mechanism of action and biological rationale, results of the CD study)
Prof. Mark Silverberg (data from his real-world clinical practice)

What does this discussion offer?

• A mechanism-based approach, not only an outcome-based one
• Evidence from clinical trials, translational studies and real-world clinical practice
• Direct applicability to the management of patients with IBD

Format

• 100% online training
• High-level scientific content, focused on clinical practice

A meeting for specialists looking for new strategies – based on evidence, but also on experience and differential mechanisms – to optimize the management of IBD.

Programme

(To watch the video with subtitles in your preferred language, please go to the video/subtitle settings and select the language of your choice)

Welcome and Introduction.
Moderator: Dr. Ignacio Marín-Jiménez

Targeting inflammation at its source: the role of innate immune system.
Prof. Saurabh Mehandru

Video coming soon.

Adacolumn®: where we were and where we are today.
Dr. Iago Rodríguez-Lago

Advancing IBD care with CurQD®: current evidence, new U.S. data and personal clinical experience.
Prof. Mark Silverberg

AhR molecular pathway: the rise of a unique mechanism linking diet, microbiome and IBD.
Prof. Shomron Ben-Horin

Discussion and closing remarks.